Sign In
Buy IFRX
$1.70
-0.0200 (-1.16%)
At Close: Jul 31, 2026
Do Insiders Own Shares In InflaRx N.V. (NASDAQ:IFRX)?
04:43pm, Friday, 19'th Jul 2019
If you want to know who really controls InflaRx N.V. (NASDAQ:IFRX), then you'll have to look at the makeup of its...
InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
08:01pm, Thursday, 18'th Jul 2019
InflaRx (IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today reported additional in-depth analysis of the completed do
InflaRx Enters Oversold Territory
01:55pm, Thursday, 18'th Jul 2019
InflaRx has been on a bit of a cold streak lately.
Hedge Funds Have Never Been This Bullish On InflaRx N.V. (IFRX)
03:31am, Sunday, 30'th Jun 2019
Does InflaRx N.V. (NASDAQ:IFRX) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright inte
InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum
01:00pm, Thursday, 13'th Jun 2019
InflaRx N.V. (IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the treatment of the first patient in a phase
InflaRx shares plummet over 90% after drug test failure
08:18pm, Wednesday, 05'th Jun 2019
InflaRx shares plummet over 90% after the biotech company said its drug for an inflammatory skin disorder failed to show a show a significant response compared to a placebo. The drug, called IFX-1, is
InflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
11:49am, Wednesday, 05'th Jun 2019
IFX-1 did not demonstrate a statistically significant dose dependent effect on Hidradenitis Suppurativa Clinical Response (HiSCR) rate at week 16 as primary endpoint IFX-1.
InflaRx N.V. (IFRX) Reports Q1 Loss, Lags Revenue Estimates
01:15pm, Thursday, 23'rd May 2019
InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 30.65% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
InflaRx Reports First Quarter 2019 Financial & Operating Results
12:00pm, Thursday, 23'rd May 2019
IFX-1: New long-term efficacy data from Phase IIa clinical trial in Hidradenitis Suppurativa presented; approval granted to initiate Phase IIa trial in Canada in Pyoderma.
InflaRx (IFRX) Catches Eye: Stock Jumps 7.5%
12:45pm, Wednesday, 10'th Apr 2019
InflaRx (IFRX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
